These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 8658272

  • 21. [The clinical and microbiological study of the preparation perfloxacin in treating urologic infections].
    Dragiev D, Savov E, Lilov A, Tsenova Z, Saltirov I, Atanasova I.
    Khirurgiia (Sofiia); 1993; 46(4):49-51. PubMed ID: 8041098
    [Abstract] [Full Text] [Related]

  • 22. [Studies of lomefloxacin in biliary tract infections].
    Ono Y, Kunii O.
    Jpn J Antibiot; 1989 Apr; 42(4):1017-24. PubMed ID: 2769934
    [Abstract] [Full Text] [Related]

  • 23. [Development of resistance and utilization of fluoroquinolones in a university hospital].
    Vlcek J, Pozlerová E, Lonská V, Kotlár J.
    Ceska Slov Farm; 1997 Oct; 46(5):195-8. PubMed ID: 9600142
    [Abstract] [Full Text] [Related]

  • 24. [In vitro evaluation of lomefloxacin].
    Dette GA, Knothe H.
    Arzneimittelforschung; 1989 Aug; 39(8):832-5. PubMed ID: 2818672
    [Abstract] [Full Text] [Related]

  • 25. [Should fluoroquinolones be restricted in hospitals?].
    Shah PM.
    Enferm Infecc Microbiol Clin; 1990 Aug; 8(6):336-7. PubMed ID: 2081166
    [No Abstract] [Full Text] [Related]

  • 26. Efficacy of the combination of levofloxacin plus ceftazidime in the treatment of hospital-acquired pneumonia in the intensive care unit.
    Bassetti M, Righi E, Rosso R, Mannelli S, Di Biagio A, Fasce R, Pallavicini FB, Marchetti F, Viscoli C.
    Int J Antimicrob Agents; 2006 Dec; 28(6):582-5. PubMed ID: 16979877
    [Abstract] [Full Text] [Related]

  • 27. [New quinolones for the treatment of community-acquired pneumonia--pro].
    Zimmerli S.
    Dtsch Med Wochenschr; 2003 May 09; 128(19):1070. PubMed ID: 12736859
    [No Abstract] [Full Text] [Related]

  • 28. [New quinolones for the treatment of community-acquired pneumonia--contra].
    Egger M.
    Dtsch Med Wochenschr; 2003 May 09; 128(19):1071. PubMed ID: 12736860
    [No Abstract] [Full Text] [Related]

  • 29. Prophylaxis in transurethral surgery: oral lomefloxacin versus intravenous cefuroxime.
    Martín-Luengo F, Fontana L, Rico JL, Tomás-Ros M, Murcia A, Romero A.
    Methods Find Exp Clin Pharmacol; 1993 May 09; 15(1):57-9. PubMed ID: 8386794
    [Abstract] [Full Text] [Related]

  • 30. Overview of quinolones in the treatment and prevention of surgical infection.
    Weigelt JA.
    Am J Surg; 1998 Dec 09; 176(6A Suppl):4S-7S. PubMed ID: 9935249
    [Abstract] [Full Text] [Related]

  • 31. Diagnosis and treatment of community-acquired and hospital-acquired pneumonia.
    Foster MT.
    Pharmacotherapy; 1993 Dec 09; 13(2 Pt 2):45S-50S. PubMed ID: 8474938
    [Abstract] [Full Text] [Related]

  • 32. Epidemiology of bacterial infection during management of open leg fractures.
    Carsenti-Etesse H, Doyon F, Desplaces N, Gagey O, Tancrède C, Pradier C, Dunais B, Dellamonica P.
    Eur J Clin Microbiol Infect Dis; 1999 May 09; 18(5):315-23. PubMed ID: 10421037
    [Abstract] [Full Text] [Related]

  • 33. Journal of Managed Care Pharmacy. START (Stewardship Tactics for Antimicrobial Resistance Trends). Introduction.
    Rodvold KA.
    J Manag Care Pharm; 2009 Mar 09; 15(2 Suppl):S3-4. PubMed ID: 19358369
    [No Abstract] [Full Text] [Related]

  • 34. Antimicrobial activity of E-4441, a representative azetidine quinolone.
    Esteve M, Moros M, Coll R, Xicota MA, Llovera S.
    Drugs Exp Clin Res; 1990 Mar 09; 16(9):445-9. PubMed ID: 2100245
    [Abstract] [Full Text] [Related]

  • 35. The impact of fluoroquinolones use on antibiotic resistance in an intensive care burn department.
    Thabet L, Memmi M, Turki A, Messadi AA.
    Tunis Med; 2010 May 09; 88(5):297-300. PubMed ID: 20517823
    [Abstract] [Full Text] [Related]

  • 36. The quinolones.
    Neu HC.
    Infect Dis Clin North Am; 1989 Sep 09; 3(3):625-39. PubMed ID: 2671143
    [Abstract] [Full Text] [Related]

  • 37. Antimicrobial resistance in nosocomial bloodstream infection associated with pneumonia and the value of systematic surveillance cultures in an adult intensive care unit.
    Depuydt PO, Blot SI, Benoit DD, Claeys GW, Verschraegen GL, Vandewoude KH, Vogelaers DP, Decruyenaere JM, Colardyn FA.
    Crit Care Med; 2006 Mar 09; 34(3):653-9. PubMed ID: 16505649
    [Abstract] [Full Text] [Related]

  • 38. [New indications for novel fluoroquinolones: moxifloxacin in the treatment of nosocomial infections].
    Beloborodova NV, Popov DA, Vostrikova TIu, Bachinskaia EN, Kuznetsova ST.
    Antibiot Khimioter; 2009 Mar 09; 54(1-2):25-6, 28-30. PubMed ID: 19499714
    [No Abstract] [Full Text] [Related]

  • 39. Drug not considered a first-line agent.
    Lexchin J.
    Can Fam Physician; 1998 Nov 09; 44():2376. PubMed ID: 9839049
    [No Abstract] [Full Text] [Related]

  • 40. High-dose intravenous fluoroquinolones in the treatment of severe infections.
    Modai J.
    J Chemother; 1999 Dec 09; 11(6):478-85. PubMed ID: 10678789
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.